{"schema_version":"secwatch.filing_event.v1","accession":"0001645113-23-000038","form_type":"8-K","ticker":"NVCR","cik":"0001645113","company_name":"NovoCure Ltd","filed_at":"2023-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.816695+00:00","generated_at":"2026-06-15T22:13:57.780171+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Novocure Q1 2023: Revenue down 11% to $122M, net loss $53.1M, prescriptions up 8%","bullets":["Total net revenues $122.2M (-11% YoY); US $85.2M, Germany $15.1M, Japan $8.7M.","Net loss $53.1M ($0.50 loss per share); adjusted EBITDA -$18.4M.","Prescriptions received 1,496 (+8% YoY); active patients 3,467 as of March 31.","R&D expenses +41% to $59.7M on clinical trial activity; sales & marketing +35%.","Phase 3 LUNAR NSCLC data to be presented at ASCO June 6; METIS enrollment completed, data Q1 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001645113-23-000038","json":"https://secwatch.observer/filing/0001645113-23-000038.json","markdown":"https://secwatch.observer/filing/0001645113-23-000038.md","text":"https://secwatch.observer/filing/0001645113-23-000038.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000038/0001645113-23-000038-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000038/nvcr-20230504.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T22:13:57.780171+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bcc4056b484b6f3db4b12af5f972145b3c19bae9","claim":"NovoCure Ltd reported quarter ended March 31, 2023 results: revenue $122.2 million, net income $53.1 million, EPS $0.50.","evidence_excerpt":"Financial updates for the first quarter ended March 31, 2023: • Total net revenues for the quarter were $122.2 million, a decrease of 11% compared to the same period in 2022. ◦ The United States, Germany and Japan contributed $85.2 million, $15.1 million and $8.7 million in quarterly net revenues, respectively, with our other active markets contributing $7.9 million. ◦ Revenue in Greater China from Novocure’s partnership with Zai Lab totaled $5.3 million. • Gross margin for the quarter was 76%. • Research, development and clinical studies expenses for the quarter were $59.7 million, an increase of 41% from the same period in 2022. This primarily reflects increased clinical trial and personnel costs associated with the PANOVA-3 and METIS clinical trials. Total clinical trial expenses can fluctuate quarter-to-quarter dependent upon the amount of clinical research organization services delivered, clinical materials procured and number of trials actively underway. • Sales and marketing exp","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000038/0001645113-23-000038-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended March 31, 2023"},{"label":"Revenue","value":"$122.2 million"},{"label":"Net income","value":"$53.1 million"},{"label":"EPS","value":"$0.50"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}